Back to top

oncology-screening: Archive

Ahan Chakraborty

Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?

Recursion Pharmaceuticals axes three drug programs after weak study data, but shifts focus to more promising candidates like REC-4881 to regain ground.

SDGRNegative Net Change RLAYNegative Net Change RXRXNegative Net Change